-
2022-501417-31-00
5
High-risk Resected Melanoma
-
2022-501463-40-00
5
Locally Advanced or Metastatic Cholangiocarcinoma
-
2025-523766-25-00
5
Ulcerative colitis
-
2023-509176-42-00
11
Obesity and T2D
-
2023-509392-17-00
5
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-513724-42-00
10
Medulloblastoma
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2025-521037-86-00
5
Immune system diseases
-
2025-521038-27-00
5
Immune system diseases
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521590-13-00
5
Moderately to Severely Active Crohn’s Disease
-
2025-522511-42-00
4
Crohn's disease
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523735-19-00
5
Metastatic Microsatellite Stable Colorectal Cancer
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524495-39-00
6
Chronic Rhinosinusitis with Nasal Polyps
-
2025-524877-18-00
6
Acute bacterial skin and skin structure infection (ABSSSI)
Erysipelas
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2024-519359-27-00
4
2026-04-16
Acute radiation proctitis symptoms in male patients aged 18 years or o
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma